Bimatoprost
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Bimatoprost
- Bimatoprost: From Open-Angle Glaucoma to Malformation Syndrome with Odontal and/or Periodontal Component
Bimatoprost: From Open-Angle Glaucoma to Malformation Syndrome with Odontal and/or Periodontal Component
One-Sentence Summary
Bimatoprost is a prostaglandin F2-alpha (prostamide) analog eye drop, originally used for open-angle glaucoma and ocular hypertension. The TxGNN model's top-ranked prediction is a malformation syndrome with odontal and/or periodontal component, but there are 0 clinical trials and 0 publications supporting it, so this is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma, ocular hypertension (also eyelash hypertrichosis) |
| Predicted New Indication | Malformation syndrome with odontal and/or periodontal component |
| TxGNN Prediction Score | 99.997% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, bimatoprost is a prostamide/prostaglandin F2-alpha analog. It lowers intraocular pressure in glaucoma, and it also prolongs the hair growth (anagen) phase, which explains its use for eyelash hypotrichosis.
For this top-ranked prediction, no identifiable mechanistic link was found. The score is very high, but a developmental malformation syndrome with a dental or periodontal component has no known connection to prostaglandin analog activity. The prediction most likely reflects patterns in the knowledge graph rather than biology. Without supporting trials or literature, it should not be treated as a credible repurposing lead.
Better-supported candidate among the top 10 predictions: alopecia (rank 8, score 99.993%). Here the hair-follicle mechanism is plausible, and there are 11 registered trials and 20 publications, including several Phase 2 studies (details in the Conclusion).
Clinical Trial Evidence
Currently no related clinical trials registered for the predicted indication.
Literature Evidence
Currently no related literature available for the predicted indication.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN16938P | LUMIGAN PF (Bimatoprost Ophthalmic Solution) 0.03% | Sterile solution |
| SIN14365P | LUMIGAN (Bimatoprost Ophthalmic Solution) 0.01% | Sterile solution |
| SIN13589P | Ganfort Eye Drops | Sterile solution |
| SIN14966P | GANFORT PF Eye Drops (Bimatoprost 0.3 mg/ml, Timolol 5.0 mg/ml) | Sterile solution |
All four registrations are valid and held by Allergan Pharmaceuticals Ireland. The data compiled for this report do not include approved indication text. The Ganfort products contain bimatoprost combined with timolol.
Safety Considerations
- Conditions linked to contraindication in the knowledge graph (not label text): liver disease, gallbladder disease, uveitis, iritis, iris disease, ciliary body disease, panuveitis, macular retinal edema, cystoid macular edema.
- Drug Interactions: 66 potential interactions were identified, all with an unclassified severity level. Examples include calcitriol, phentermine, pantoprazole, morphine, metformin, omeprazole, prednisone, prednisolone, triamcinolone, simvastatin and ondansetron.
Please refer to the package insert for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction is supported only by a model score (L5), with no trials, no literature and no plausible mechanism. It does not justify further investment.
To proceed, the following is needed:
- Treat this prediction as a model artifact unless disease-specific biological evidence emerges.
- If the goal is hair-related repurposing, redirect to alopecia, the best-supported candidate (evidence level L2, "Research Question"). Completed Phase 2 trials include NCT01325337 (307 men with androgenetic alopecia), NCT01325350 (306 women with female pattern hair loss) and NCT01904721 (244 men). However, they are not Phase 3 and the scalp efficacy evidence is mixed.
- Obtain the Singapore package insert (warnings, contraindications, approved indications) and detailed mechanism of action data.
- Note that the Ambras-type hypertrichosis prediction (rank 4) is mechanistically opposed, because bimatoprost promotes hair growth, and treatment could worsen that condition.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.